Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [5]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-20291 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD254 (RANK Ligand) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A suggested positive control is rat liver tissue lysate.
- Concentration
- 1 mg/mL
Submitted references Comparison of the Effect of Oral Versus Intravenous Bisphosphonate Administration on Osteoclastogenesis in Advanced-Stage Medication-Related Osteonecrosis of the Jaw Patients.
Kim HW, Lee MW, Lee JH, Kim MY
Journal of clinical medicine 2021 Jul 4;10(13)
Journal of clinical medicine 2021 Jul 4;10(13)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of rat liver tissue lysate using a CD254/sRANKL polyclonal antibody (Product # PA5-20291) at (A) 0.25 and (B) 0.5 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot Validation in Human Cell Lines. Loading: 15 µg of lysates per lane. Antibodies: CD254 (RANK Ligand) Polyclonal Antibody (Product # PA5-20291) (1 µg/mL), 1h incubation at RT in 0.05 NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10,000 dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot Validation in Mouse Tissues. Loading: 15 µg of lysates per lane. Antibodies: CD254 (RANK Ligand) Polyclonal Antibody (Product # PA5-20291) (2 µg/mL), 1h incubation at RT in 0.05 NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10,000 dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot Validation in Rat Liver Tissue. Loading: 15 µg of lysates per lane. Antibodies: CD254 (RANK Ligand) Polyclonal Antibody (Product # PA5-20291) (A: 0.25 µg/mL and B: 0.5 µg/mL), 1h incubation at RT in 0.05 NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10,000 dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot Validation with Recombinant Protein. Loading: 30 ng of human sRANK-L recombinant protein per lane. Antibodies: CD254 (RANK Ligand) Polyclonal Antibody (Product # PA5-20291) (A: 1 µg/mL, B: 2 µg/mL and C: 4 µg/mL), 1h incubation at RT in 0.05 NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10,000 dilution. Observed at around 27 kDa.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of paraffin-embedded human liver tissue using CD254 (RANK Ligand) Polyclonal Antibody (Product # PA5-20291) at 5 µg/mL. Tissue was fixed with formaldehyde and blocked with 0.1 serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 The RANKL/OPG ratio is decreased in the necrotic bones of IV BP-induced advanced-stage MRONJ patients. ( a ) High-magnification images (400x) of the immunohistochemistry analysis of RANKL (left) and OPG (right) expression in the specimens of the two patient groups as indicated. Scale bars = 50 mum. Statistical analysis of the number of RANKL-positive ( b ), and OPG-positive ( c ) cells, and the RANKL/OPG ratio ( d ), via the Mann-Whitney U test ( n = 20 per group). deg marks statistical outliers. For detailed data, see Table 2 . * p < 0.001.